<DOC>
	<DOC>NCT00219232</DOC>
	<brief_summary>The goal of this research study is to evaluate, in the open-label extension phase, the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease</brief_summary>
	<brief_title>An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Patients who fulfilled the inclusion and exclusion criteria as listed in the study CENA713D2320 and have completed the doubleblind treatment phase on study medication without significant protocol violations.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Dementia</keyword>
</DOC>